Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

NCT05613114 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Hereditary Spastic Paraplegia

Interventions

DRUG: Dalfampridine 10 MG
DRUG: Placebo
BEHAVIORAL: Physiotherapy

Sponsor

European University of Lefke